-+ 0.00%
-+ 0.00%
-+ 0.00%

Medtronic Secures CE Mark In Europe To Expand Indications Of MiniMed 780G System For Use By Individuals Aged 2 Years And Older, During Pregnancy, As Well As Type 2 Insulin-Requiring Diabetes

Benzinga·07/21/2025 12:48:45
Listen to the news

Medtronic plc (NYSE:MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of the MiniMed™ 780G system for use by individuals aged 2 years and older, during pregnancy, as well as type 2 insulin-requiring diabetes. To gain CE Mark for this expansion of indications, published clinical data in 2–6-year-olds, pregnant women, and people living with type 2 diabetes was reviewed. This expanded indication underscores the commitment Medtronic has to advancing access to automated insulin delivery (AID) technology for broader and more diverse populations, helping to improve outcomes and quality of life for people at every stage of life living with diabetes.